Scientists test new weapon in fight against aggressive blood cancer
NCT ID NCT04323956
Summary
This early-stage study is testing if adding a new drug called parsaclisib to a standard chemotherapy regimen (R-CHOP) is safe and more effective for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma. The main goals are to find the safest dose of the new combination and see if it helps more patients achieve a complete response. It is for adults with specific high-risk features of this aggressive blood cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.